Cargando…

Human normal immunoglobulin in the treatment of primary immunodeficiency diseases

The primary antibody deficiency syndromes are a rare group of disorders that can present at any age, and for which delay in diagnosis remains common. Replacement therapy with immunoglobulin in primary antibody deficiencies increases life expectancy and reduces the frequency and severity of infection...

Descripción completa

Detalles Bibliográficos
Autor principal:	Wood, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333462/ https://www.ncbi.nlm.nih.gov/pubmed/22547934 http://dx.doi.org/10.2147/TCRM.S22599

Ejemplares similares

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
por: Alsina, Laia, et al.
Publicado: (2021)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
por: Kriván, Gergely, et al.
Publicado: (2022)

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies
por: Goudouris, Ekaterini Simões, et al.
Publicado: (2017)

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
por: Schroeder, H. W., et al.
Publicado: (2012)

Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency
por: Berger, Melvin
Publicado: (2008)

Erratum: II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies
Publicado: (2017)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Gene Editing for the Treatment of Primary Immunodeficiency Diseases
por: Rai, Rajeev, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency
por: Salerno, Sara N., et al.
Publicado: (2022)

Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment
por: Espanol, Teresa, et al.
Publicado: (2014)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
por: Epland, Kristin, et al.
Publicado: (2022)

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
por: Kanegane, Hirokazu, et al.
Publicado: (2014)

Primary Immunodeficiency Diseases
por: Baltimore, Robert S.
Publicado: (1984)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
por: Gill, Parwinder K., et al.
Publicado: (2018)

Primary immunodeficiency diseases in the newborn
por: Ozdemir, Oner
Publicado: (2021)

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
por: Fasshauer, Maria, et al.
Publicado: (2023)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
por: Ricci, Silvia, et al.
Publicado: (2020)

Primary immunodeficiency
por: McCusker, Christine, et al.
Publicado: (2011)

Primary immunodeficiency
por: McCusker, Christine, et al.
Publicado: (2018)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Recent advances in treatment of severe primary immunodeficiencies
por: Gennery, Andrew
Publicado: (2015)

Factors Regulating Immunoglobulin Production by Normal and Disease-Associated Plasma Cells
por: Jackson, David A., et al.
Publicado: (2015)

The Development of a New Questionnaire to Measure the Burden of Immunoglobulin Treatment in Patients with Primary Immunodeficiencies: The IgBoT-35
por: Jones, Georgina L, et al.
Publicado: (2020)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

History of Primary Immunodeficiency Diseases in Iran
por: Aghamohammadi, Asghar, et al.
Publicado: (2010)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Eosinophilia and Increased Immunoglobulin E: Is It Really a Primary Immunodeficiency? A Diagnostic Challenge
por: Öztürk, Gökcan, et al.
Publicado: (2023)

Primary Immunodeficiency Disease Mimicking Pediatric Bechet’s Disease
por: Shiraki, Mayuka, et al.
Publicado: (2021)

Update in primary immunodeficiencies
por: Leonardi, Lucia, et al.
Publicado: (2020)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy
por: Wasserman, Richard L., et al.
Publicado: (2017)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6te3lcp6dqjd9ep5otmqtss2oo